Evidence map›Paper›PMID 35575089›Full record

ReviewThe Journal of clinical investigation2022

Biological aging processes underlying cognitive decline and neurodegenerative disease.

Mitzi M Gonzales, Valentina R Garbarino, Erin Pollet, Juan P Palavicini, Dean L Kellogg, Ellen Kraig, Miranda E Orr

Open access · goldAbstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 6 pooled it
23.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 6 syntheses or guidelines pooled it, 313 citations in OpenAlex.

  1. Repetitive transcranial magnetic stimulation for cognitive and emotional symptoms in neurodegenerative diseases: a systematic review and dose-response meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Relative impact of multidomain lifestyle interventions on deficit accumulation frailty over 24 months in the U.S. POINTER trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Trial
  9. Trial
  10. Article
  11. Article
  12. Effects of obesity on brain health and cognition.Nature reviews. Neurology · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mitzi M GonzalesGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases.
Valentina R GarbarinoGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases.
Erin PolletGlenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases.
Juan P PalaviciniBarshop Institute for Longevity and Aging Studies, and.
Dean L KelloggBarshop Institute for Longevity and Aging Studies, and.
Ellen KraigBarshop Institute for Longevity and Aging Studies, and.
Miranda E OrrGerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Institute for Neurodegenerative Disorders · USThe University of Texas Health Science Center at San Antonio · USWake Forest University · US

Funding

TRANSGENIC COREP30AG013319 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JAMES FLOYD NELSON · 1995 to 2026
$30.6M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0M
San Antonio OAIC - Research Education Component (REC)P30AG044271 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Adam Salmon, Elena Volpi · 2015 to 2026
$14.1M
TRAINING GRANT ON THE BIOLOGY OF AGINGT32AG021890 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Erzsebet Kokovay, JAMES FLOYD NELSON · 2003 to 2026
$11.4M
Pepper OAIC Coordinating CenterU24AG059624 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DALANE W KITZMAN · 2018 to 2026
$6.0M
An innovative proof-of-concept approach to identify age-modulating drugs capable of reversing inflammation and re-setting the epigenetic clockR21AG068731 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KELLOGG, DEAN L, KRAIG, ELLEN · 2020 to 2021
$424k
NIA NIH HHS P30 AG013319NIA NIH HHS P30 AG044271NIA NIH HHS P30 AG066546NIA NIH HHS P30AG066546NIA NIH HHS P30 AG072947NIA NIH HHS R21 AG068731NIA NIH HHS T32 AG021890NIA NIH HHS U24 AG059624
6 · The paper itself

Abstract

Alzheimer's disease and related dementias (ADRD) are among the top contributors to disability and mortality in later life. As with many chronic conditions, aging is the single most influential factor in the development of ADRD. Even among older adults who remain free of dementia throughout their lives, cognitive decline and neurodegenerative changes are appreciable with advancing age, suggesting shared pathophysiological mechanisms. In this Review, we provide an overview of changes in cognition, brain morphology, and neuropathological protein accumulation across the lifespan in humans, with complementary and mechanistic evidence from animal models. Next, we highlight selected aging processes that are differentially regulated in neurodegenerative disease, including aberrant autophagy, mitochondrial dysfunction, cellular senescence, epigenetic changes, cerebrovascular dysfunction, inflammation, and lipid dysregulation. We summarize research across clinical and translational studies to link biological aging processes to underlying ADRD pathogenesis. Targeting fundamental processes underlying biological aging may represent a yet relatively unexplored avenue to attenuate both age-related cognitive decline and ADRD. Collaboration across the fields of geroscience and neuroscience, coupled with the development of new translational animal models that more closely align with human disease processes, is necessary to advance novel therapeutic discovery in this realm.

Indexed as

Alzheimer DiseaseCognitive DysfunctionNeurodegenerative DiseasesAgingAnimalsCognition

Identifiers

PMID35575089
PMCPMC9106343
OpenAlexW4280531467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.